drugset / Trial / NCT00314743
Efficacy & Safety of the Oral Neurokinin-1 Antagonist, Aprepitant, in Combo With Ondansetron & Dexamethasone in Patients Undergoing Auto Peripheral Blood Stem Cell Transplantation
RandomizedParallel-groupOpen-labelSupportive care
Summary
The purpose of this study is to determine the efficacy of aprepitant in preventing acute and delayed chemotherapy induced nausea and vomiting when administered in combination with intravenous or oral ondansetron and intravenous or oral dexamethasone in the autologous transplant setting.
Timeline
- Start
- 2005-10
- Primary completion
- 2008-12
- Completion
- 2008-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aprepitant | Other / unclassified | 80 mg | Oral |
| Subject | Dexamethasone | Small molecule | 10 mg | Intravenous |
| Subject | Dexamethasone | Small molecule | 20 mg | Intravenous |
| Background | Ondansetron | Other / unclassified | 32 mg | Intravenous |
Indications
No indication recorded.